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Host-guest complexes exhibiting a 1:1 binding stoichiometry need not consist of a single host
and guest. A series of oligopeptides, which were previously reported to have abnormally high
binding enthalpies were investigated to deduce whether they exist as a 2:2 quaternary or a 1:1
binary complex with cucurbit[8]uril (CB[8]). Through a systematic study of the sequence-specific
binding pathways of peptide-CB[8] association, a phenylalanine-leucine dipeptide was found to
be capable of switching from a 1:1 stoichiometric complex to a 2:1 complex. By studying the
differences in size-based diffusion properties of these two binding modes, the presence of a 1:1
pairwise inclusion complex was verified for the regime where CB[8] is in excess. Findings in this
study can be utilised to ‘customise’ the precise CB[8]-oligopeptide self-assembly pathway, acting
as a useful toolbox in the design of supramolecular systems.
1 Introduction
Cucurbit[n]urils (CB[n]) are a family of synthetic macrocyclic
host molecules capable of encapsulating a wide range of organic
guests in aqueous media with exceptional affinity.1–4 They have
also been shown to bind with biomolecules such as amino acids,
peptides, and proteins; demonstrating a preference for aromatic
residues such as tryptophan (W), phenylalanine (F), and tyrosine
(Y).5,6 Among the cucurbituril homologues, CB[8] is versatile
on account of its ability to form both hetero- and homoternary
complexes with these amino acids, accommodating two differ-
ent guests (e.g. methyl viologen and tryptophan5) or two iden-
tical guests, respectively (e.g. phenylalanine6). The discovery of
CB[8]-mediated ternary complexes has led to their application in
molecular4 or chiral7 recognition, supramolecular catalysis,8–10
and engineered nanostructures.11,12
The host-guest binding of CB[n] in aqueous media is mainly
driven by the release of energetically-frustrated cavity-bound wa-
ter (high-energy water),13,14 whereby free energy is contributed
mostly from enthalpy and is directly related to the number of wa-
ter molecules that are displaced. For instance, the formation of
a binary complex in aqueous solution typically will release less
heat than the formation of a ternary complex, as only one guest
displaces a smaller number of cavity-bound water molecules.15
This means that the enthalpy change from binding can provide
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Fig. 1 a) Thermodynamic data of CB[8]-mediated complexations in-
cluding 2:1 homoternary (blue circles), 1:1:1 heteroternary (red circles),
1:1 binary (green circles), 2:2 quaternary (purple square), 15 and "1:1"
peptide-CB[8] complexes (crosses), where the yellow crosses represent
data previously reported by Urbach et al. 16,17 and orange crosses repre-
sent data collected in this work. The two possible binding motifs to be dis-
tinguished and verified are b) one CB[8] encapsulating two neighboring
amino acid residues from one peptide within its cavity and c) two CB[8]
each of which encapsulates two residues from two antiparallel-aligned
peptides. N.B. The dipeptide backbones (with green carbons) are not
derived from computational simulation results but are directly taken from
existed FF dipeptide crystals.
Recently, unique CB[8]-mediated complexes of 1:1 binding sto-
ichiometry have also been observed.15–19 These complexes have
exhibited abnormally large binding enthalpies when compared to
typical enthalpy changes for 1:1 binary complexation (Fig. 1a).
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Through further exploration of this phenomena, we found that
diaryl-viologens attributed with electron-donating substituents as
well as azobenzene derivatives preferred to form 2:2 quaternary
complexes with CB[8].15,18 In these complexes, two partially-
stacked guests are ‘clamped’ together by two CB[8] macrocycles
resulting in a multi-component complex whose exchange dynam-
ics are substantially retarded compared to typical binary com-
plexes (henceforth referred to as ‘static’ throughout). Other ex-
amples of 1:1 binding stoichometry exhibiting abnormally high
binding enthalpy are the association of CB[8] with sequence-
specific tripeptides such as tyrosine-leucine-alanine (YLA)16 and
methionine-leucine-alanine (MLA)17 both reported by Urbach et
al.16,17 Although a binding motif was proposed where one CB[8]
accommodated two neighbouring amino acid residues within the
cavity (Fig. 1b),16 their computational simulations were solely
based on a 1:1 binary model. The simulations did not take into
account other possible n:n stoichometric binding modes such as
a 2:2 quaternary complex, where each CB[8] encapsulates two
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Fig. 2 The association of peptides with CB[8] often takes place along
two typical pathways: a) Path A, involves a sequential formation of the
binary and homo-ternary complex with increasing peptide to CB[8] ratio,
a typical case is Phe-Gly-Gly (FGG); 6,20 b) Path B, involves the forma-
tion of a “1:1” stoichometric complex, in which CB[8] encapsulates two
residues in a ternary manner and remains unaltered even in the pres-
ence of excess peptide, a typical case is Tyr-Leu-Ala (YLA). 16 Herein,
we pursue a peptide that c) associates with CB[8] along Path B when
excess CB[8] is present and turns to Path A when peptide is in excess.
d) Through comparing the size or diffusion coefficent of the complex in
these two different configurations, we can confirm the binding model of
the “1:1” stoichometric complex.
The practicality of distinguishing between binding motifs of the
same stoichometry, especially for systems with small differences
such as oligopeptide-CB[8] complexes, remains extremely chal-
lenging. Both 1:1 and 2:2 binding motifs depicted in Fig. 1 can
readily explain the large enthalpy changes observed (Fig. 1, Ta-
ble S1), as the CB[8] in either motif includes two pendant groups
within its cavity, resembling ternary complexation. The 1H-NMR
and ROESY studies of the YLA@CB[8] complex revealed that both
the side-chains of the Y and L resided inside the CB[8] cavity
and were in close proximity to one another.16 However, it cannot
be distinguished whether the Y and L is derived from the same
tripeptide (Fig. 1b) or from two antiparallel-aligned YLA peptides
(Fig. 1c).
The most abundant signals detected by mass spectrometry (in
the gas phase) do not necessarily correlate to the most abundant
species in solution, especially for such complexes, which is driven
by desolvation.15,21 Direct injection of a 2:2 diarylviologen-CB[8]
solution yields an intense signal, which corresponds to the com-
plex consisting of one guest with one CB[8], suggesting the dis-
sociation of 2:2 complexes in the gas phase.15 Analysing signals
of lower intensity in the mass spectrum of YLA@CB[8] we ob-
served various aggregation species that contained multiple CB[8]
and multiple peptide molecules (Fig. S14), which did not al-
low us to distinguish between the two binding modes. More-
over, YAL@CB[8] exhibits almost the same mass spectrum as
YLA@CB[8] in gas phase (Fig. S13-16), although their bindings
in aqueous solution are completely different. In light of these ob-
servations, it is not clear whether the 1:1 stoichometric binding
mode of a peptide-CB[8] complex exists as either a 1:1 binary
complex or a 2:2 quaternary complex.
One possible approach is to detect size-based diffusion prop-
erties of different binding modes using in situ techniques like
diffusion ordered spectroscopy (DOSY). However, the results de-
rived from DOSY NMR are often susceptible to molecular proper-
ties and strongly correlate to the experimental and instrumental
conditions. For instance, one cannot readily distinguish if the
small difference in diffusion coefficients observed between the
FGG2@CB[8] and YLA@CB[8] systems is caused by the struc-
tural differences of the oligopeptides or by their different binding
modes with CB[8], or merely due to apparatus error. Therefore,
devising a system that can display different binding modes with a
minimum perturbation to the system parameters is highly desir-
able.
Herein, we revisit the sequence-specific binding behaviour of
oligopeptides with CB[8], to deduce whether they exist as a 2:2
or a 1:1 binary complex with CB[8](Fig. 2). We hypothesised that
by investigating the differences in size-based diffusion properties,
it would allow us to distinguish between the different binding
modes. To facilitate this size comparison, we designed and stud-
ied oligopeptide sequences in an attempt to program a versatile
complex that can exhibit both a 1:1 stoichometry (either 1:1 or
2:2) when excess CB[8] is present and a 2:1 complex when the
peptide is in excess (Fig. 2c). Subsequently, by comparing the
sizes of the formed complexes in these two regimes, we will be
able to distinguish a 1:1 pairwise inclusion from a 2:2 quaternary
complex, as the size of 1:1, 2:1, and 2:2 species have ascending
molecular sizes (Fig. 2d).
2 Results and Discussion
To generate the desired versatile system, which can switch be-
tween 1:1 and 2:1 binding modes, our peptide design would need
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to suppress the 1:1 path B and maximise the 2:1 path A in condi-
tions with excess peptide. Therefore, the effects of altering the se-
quence on binding behaviour was studied, including the sequen-
tial order of the effective residues, as well as chain extension at

































































Fig. 3 Association of YL with CB[8] following Path B, demonstrated by
1H-NMR spectra of a) the YL@CB[8] complex with 1:1 stoichiometry, b)
YL in D2O solution at 298 K, where the concentration of CB[8] is 0.1 mM,
and c) the signal splitting of CB[8] protons during the titration of YL, as
well as d) the isothermal titration calorimetry of YL into CB[8] in 10 mM
sodium phosphate buffer (pH 7.0) at 298 K. Two individual titrations were
performed for a subsequent global fitting. N.B. the intensity of H j in b) is
smaller than it supposes to be due to solvent suppression in NMR.
2.1 Association of YL and LY oligopeptide derivatives with
CB[8]
Several YL and LY oligopeptide derivatives including YL, YLA,
YLAA, AAYLAA, LY, LYA, ALY were synthesised and their com-
plexation with CB[8] studied using a combination of NMR titra-
tions and isothermal titration calorimetry (ITC) techniques. NMR
titration studies of YL and LY oligopeptide derivatives against
CB[8] all exhibited similar proton shifts and splitting patterns
corresponding to binding typical for Path B, where both Y and
L sidechains resided inside the CB[8] cavity in close proximity to
one another. As exemplified by YL@CB[8] in Fig. 3a, the proton
signals from the side-chains of Y (Hc,d,h) and L (Ha,b,e, f ) were sig-
nificantly shifted upfield compared with the signals of unbound
YL (Fig. 3b), demonstrating the encapsulation of both side-chains
inside the CB[8] cavity. The inclusion of a proton inside a CB[8]
cavity contributes to a shift of approximately 1 ppm22, thus the
upfield shift of H f by more than 2.5 ppm (Fig. 3a,b) must also
be a product of the aromatic ring current from the tyrosine side-
chain and confirms the close proximity of the phenol ring of Y
and the isobutyl group of L inside the CB[8] cavity (Fig. 3a).
This results in an asymmetric chemical environment within the
cavity where previously equivalent protons are no longer chemi-
cally equivalent, resulting in two set of signals for each proton in
Hc,d,h,e (Fig. 3b). Meanwhile, the observation of inequivalent pro-
tons as two sets of signals also suggests the formation of a ’static’
YL@CB[8] complex with a slow flipping rate of the enclosed phe-
nol and isobutyl groups on the NMR timescale. This asymmetric
environment coupled with a slow flipping rate can also be demon-
strated by the signal splitting of CB[8] protons (Hx,y,z), as shown
in Fig. 3c.
ITC studies (Fig. 3d) also demonstrated a 1:1 stoichiometric
binding of YL with CB[8], having an affinity of 8.2×106 M−1 and
an enthalpy change of -13.6±0.1 kcal/mol (Table 1), which cor-
responds to the association of CB[8] in a ternary manner with a
typical enthalpy change between -12 and -18 kcal/mol(Fig. 1).
Table 1 Thermodynamic data for the associated CB[8] with peptide
derivatives of YL, LY, and FL. All the data is obtained from ITC at 298 K in
10 mM sodium phosphate buffer (pH 7.0), whose individual titration plots
can be found in the ESI.
Peptides Ka ∆G ∆H T ∆S
(M−1 or M−2) (kcal/mol) (kcal/mol) (kcal/mol)
YL 8.2×106 -9.4±0.1 -13.6±0.1 -4.2±0.2
YLA 8.1×106 -9.4±0.1 -12.0±0.1 -2.6±0.2
YLAA 7.1×106 -9.3±0.1 -11.0±0.1 -1.7±0.2
AAYLAA 1.8×105 -7.2±0.1 -11.6±0.1 -4.4±0.2
LY 1.3×107 -9.7±0.2 -13.7±0.2 -4.0±0.4
LYA 1.3×107 -9.7±0.2 -12.0±0.2 -2.3±0.3
ALY 1.3×106 -8.4±0.1 -11.7±0.1 -3.4±0.1
FLA 1.0×107 -9.6±0.1 -12.0±0.1 -2.4±0.1
AFLA 2.1×106 -8.6±0.1 -11.4±0.1 -2.8±0.1
LF 6.6×106 -9.3±0.2 -12.3±0.2 -3.0±0.4
FL (Path B) 1.3×107 -9.7±0.8 -11.4±0.2 -1.7±1.0
FL (Path A) 1.9×1011 -15.4±2.4 -26.7±1.4 -11.3±3.8
2.2 Effects of the chain extension from C- or N-terminus and
sequential order of residues on Path B
As YL@CB[8] exhibits exactly the same binding behaviour as Ur-
bach et al. previously reported for their tripeptide systems such
as YLA@CB[8],16 we can confirm here that the shortest oligopep-
tide chains capable of forming 1:1 binding along Path B are dipep-
tide sequences such as YL and LY. The thermodynamic data of
various oligopeptide derivatives of YL and LY in Table 1 suggest
that their affinities with CB[8] are not significantly altered by ex-
tending the peptide chain at the C-terminus. YL, YLA, and YLAA
exhibited a uniform binding constant (Ka) and ∆G regardless of
the additional Ala extended from C-terminus of leucine. The ex-
tra Ala units were found to affect association through a reduction
in binding enthalpy (∆H), however, this was compenstated by a
change in entropy likely due to solvent reorgnization.23
A reduction in binding affinity can be achieved by shifting the
effective binding pair away from the N-terminus. For instance,
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AAYLAA contains an additional two Ala units extended from the
N-terminus of tyrosine exhibiting a binding affinity with CB[8]
of 1.8× 105 M−1, which is weaker than that of YL, YLA, and
YLAA by more than one order of magnitude (Table 1). The same
was observed for LY, LYA and ALY, where the binding affinity of
LY@CB[8] is the same as that for LYA@CB[8], but is one order
of magnitude stronger than that of ALY@CB[8] (Table 1). There-
fore, the 1:1 binding along Path B may be suppressed by chain
extension from the N-terminus but is not significantly influenced
by chain extension at the C-terminus.
Comparing the changes in the free energies of association for
YL@CB[8] and YLA@CB[8] (-9.4±0.1 kcal/mol) with LY@CB[8]
and LYA@CB[8] (-9.7±0.2 kcal/mol) (Table 1), the similar values
dectected suggest that the sequential order of the effective bind-














































Fig. 4 Isothermal titration calorimetry of a) FLA, b) FL, c) LF, and d)
AFLA into CB[8] in 10 mM sodium phosphate buffer (pH 7.0) at 298 K.
For each species, at least two individual titrations were performed for
the subsequent global fitting. In order to turn the binding from Path B
to Path A when excess peptide is present, a dipeptide is required rather
than a tri- or tetra- peptide, with phenylalanine at the N-terminus and
leucine at the C-terminus, i.e. FL.
2.3 Effects of C- or N-terminus chain extension on Path A
Effective 2:1 homoternary binding following Path A requires the
presence of F (phenylalanine) and is not observed with other aro-
matic residues such as Y and W (tryptophan).6 In a 2:1 binding
mode, only one residue per oligopeptide is engaged with CB[8] so
there is no obvious influence from the sequential order of the pep-
tide chain. However, the binding of a 2:1 homoternary complex
with CB[8] is highly susceptible to the position of F in the pep-
tide chain. With F positioned at the N-terminus, the homoternary
complex of FGG with CB[8] exhibited a strong affinity; whilst no
effective binding was observed for the GFG and GGF sequences,
which have chain extension from N-terminus of F.6
Although the additional two glycine residues extended from the
C-terminus of F were found to facilitate the formation of a ho-
moternary complex with CB[8],6 Cavatorta et al. demonstrated
that further chain extensions from C-terminus reduce the binding
affinity.20 Thus, 2:1 binding along Path A can be suppressed by
chain extension from either the C- or N-terminus. In other words,
Path A may be maximised by choosing the shortest sequence that
contains F at the N-terminus.
2.4 To pursue a sequence with desired binding pathway
In our effort to identify an oligopeptide that can exhibit both
Path A and Path B at different ratios of peptide to CB[8], we
decided to investigate a peptide similar to YLA (so that it can
form a 1:1 complex) but with a F residue in the N-terminus in
order to potentially display a 2:1 complex as well. Thus we set-
tled on the tripeptide FLA, which only exhibits 1:1 stoichome-
tric complexation,16 whereby no 2:1 complex is detected even
as the molar ratio of FLA to CB[8] approaches a value of 2.5
(Fig. 4a). As FLA does not lead to a 2:1 complexation product, it
suggests that the FLA tripeptide prefers to assemble along Path B
solely. However, based on the relationship between oligopeptide
sequence and binding behaviour described above, one may be
able to customise the overall assembly pathway by manipulating
the sequence further.
We first attempt to invert the sequence order of F and L, in-
vestigating thermodynamic data of the dipeptide LF. The ITC
of LF with CB[8] is shown in Fig. 4c, which exhibits a binding
profile corresponding to an absolute 1:1 stoichiometric complex.
Second, we explore what happens when FLA is extended at the
N-terminus, leading to AFLA, which remains a 1:1 complex as
shown in Fig. 4d. Learning from YLA and YLAA, one can also
infer that chain extension of FLA from the C-terminus (FLAA)
would not lead to a significant change of binding. Finally, short-
ening the peptide backbone of FLA from the C-terminus leads to
the dipeptide FL, which may result in a peptide with the desired
properties.
2.5 Coexistence of two binding pathways of FL with CB[8]
The ITC of the FL dipeptide (Fig. 4b) exhibits an obvious two-
stage binding profile that differs from the typical 1:1 binding pro-
file exhibited by FLA (Fig. 4a). A turning point is evident in the
ITC at the FL:CB[8] ratio around 1:1, which likely corresponds
to a 1:1 binding behaviour represented in Path B. A second stage
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in the binding curve appears above the 1:1 ratio resembling a














(d) FGG:CB[8] = 2:1
(c) FL:CB[8] = 3.6:1
(a) FLA:CB[8] = 1:1
(b) FL:CB[8] = 0.9:1














Fig. 5 1H-NMR spectra of a) FLA:CB[8]=1:1, b) FL:CB[8]=0.9:1, c)
FL:CB[8]=3.6:1, d) FGG:CB[8]=2:1, e) FL in D2O solution at 298 K, where
concentrations of CB[8] are all 0.1 mM and demonstrates the evolution of
binding from FLA-type pathway to FGG-type pathway. A complete NMR
titration spectra can be found in Fig. S36
Analysis of NMR titration spectra at different FL:CB[8] ratios
(Fig.S36) resulted in a few important observations. First, in the
presence of excess CB[8], e.g. FL:CB[8]=0.9:1 (Fig. 5b), the
NMR spectrum replicates that of FLA@CB[8] (Fig. 5a) with a
characteristic 1:1 stoichometric binding mode. Second, both the
CB[8] and F residue protons exhibit signal splitting. Third, the L
residue protons exhibit significant upfield shifts. All of these ob-
servations indicate the formation of a 1:1 YLA@CB[8]-type com-
plex that corresponds to Path B.
Upon further increasing the FL:CB[8] ratio, a completely dif-
ferent NMR spectrum is observed (Fig. 5 & Fig.S36), where the
peaks corresponding to the protons of the F and L side-chains
broaden and merge together. At a ratio of FL:CB[8]=3.6:1
(Fig. 5c), the signals from the isobutyl group of L (e.g Hn,n
′
) shift
downfield compared to that of both the 1:1 complex (Fig. 5b)
and uncomplexed FL peptide (Fig. 5e). This indicates that the
side-chain of L no longer resides in the CB[8] cavity and is now
situated outside in close proximity to the portal.
Instead, a homoternary 2:1 complex is formed where two
phenyl groups are encapsulated in one CB[8] cavity. This com-
plex displays a greater upfield shift of the aromatic proton signals
(Fig. 5c) compared to the spectrum at a ratio of FL:CB[8]=0.9:1
(Fig. 5b), attributed to the aromatic ring-current effect. The char-
acteristic splitting of the CB[8] peaks also disappear at this higher
ratio, resembling that of a symmetric and equivalent environment
around the two portals. Comparing these observations to that of a
typical FGG2@CB[8] NMR spectrum (Fig. 5d), the signals corre-
sponding to the binding mode in the second stage are almost the
same except for the presence of signals from excess, uncomplexed
FL peptides.
Therefore, using a combination of ITC and NMR titration tech-
niques, a coexistence of two binding pathways can be confirmed
for the association of the FL dipeptide with CB[8]. In addition,
two distinct complexation products (1:1 and 2:1 complexation)
can be obtained by carefully controlling the FL:CB[8] ratio.
2.6 Distinguishing between 1:1 and 2:2 binding modes by
DOSY
The FL peptide exhibits the coexistence of two binding pathways
and is capable of switching from a 1:1 stoichiometric complex (ei-
ther 1:1 or 2:2) to a 2:1 complex as a function of the peptide to
CB[8] ratio. We therefore used this system to deduce whether the
characteristic 1:1 stoichometric binding mode is in fact a 1:1 bi-
nary or a 2:2 quaternary complex. Through isolating specific pep-
tide:CB[8] ratios corresponding to the different binding modes
and analysing them using DOSY NMR, size-based diffusion coef-
ficients (D) could be mapped.
First, a preliminary correlation between D and the binding
modes was obtained from the study of three well-understood
CB[8]-mediated complexes. The complexes selected in-
clude the 1:1 binary complex formed by N,N’-dimethyl-4,4-
diazapyrenium iodide (dzpy) guest, the FGG2@CB[8] complex
(2:1) and the known 2:2 complex formed with the 1,1’-bis(4-
(dimethylamino)phenyl)-[4,4’-bipyridine]-1,1’-diium (VNMe2)
guest.
Table 2 Diffusion coefficients (D) of different CB[8] complexes and their
respective guests. All the data is obtained from DOSY measurements in
D2O, where the individual DOSY spectra can be found in the ESI.
Guest Guest:CB[8] D (e−10 m2s−1)
- 0:1 3.11 (±0.01)
dzpy 1:1 3.04 (±0.01)
YL 1:1 2.95 (±0.01)
YLA 1:1 2.88 (±0.01)
FLA 1:1 2.87 (±0.01)
FL (Path B, D1) 1:1 2.86 (±0.01)
FL (Path A, D2) 2:1 2.68 (±0.01)
FGG 2:1 2.66 (±0.01)
VNMe2 2:2 2.01 (±0.01)
YLAGGALY 1:2 2.08 (±0.02)
YLA-ahx6-ALY 1:2 2.07 (±0.01)
It is evident from the DOSY results (Table 2) that the D
values correlate to the number of CB[8] macrocycles present
in the complex. The 2:2 complex of VNMe2 with CB[8]
exhibits a diffusion coefficient (2.01 e−10m2s−1) significantly
slower than the D of free CB[8] (3.11 e−10m2s−1), dzpy@CB[8]
complex (3.04 e−10m2s−1), and the FGG2@CB[8] complex
(2.66 e−10m2s−1). In other words, if the 1:1 stoichiometric com-
plex of FL with CB[8] is a 2:2 quaternary complex, it should
exhibit a much smaller D value than the confirmed 2:1 ternary
complex on account of the number of CB[8] hosts present in the
complex.
The D values are also affected by the size of moieties situated
outside the CB[8] cavity. For instance, the additional G residues
in FGG2@CB[8] slightly slows down the diffusion of the complex;
whilst the dzpy@CB[8] complex with little situated around the
CB[8] portal exhibits a D value very similar to free CB[8]. Simi-
larly, one can deduce that the 1:1 binary complex of FL and CB[8]
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should exhibit a larger D value than the 2:1 ternary complex. The
simultaneous inclusion of F and L in the binary complex will result
in a smaller amount of the dipeptide outside of the CB[8] cavity
compared to the 2:1 FGG-type complex where the L residues are
entirely situated outside the CB[8] cavity.
Therefore, the potential binary, ternary, and quaternary bind-
ing modes of FL with CB[8] should have ascending molecular
sizes and descending diffusion coefficients (Fig. 2d). By com-
paring D of the 1:1 stoichiometric complex (FL:CB[8]=0.9:1)
to the 2:1 homoternary complex (FL:CB[8]=3.6:1), one should
be able to distinguish between 1:1 and 2:2 binding modes
and provide insight on the unknown nature of the 1:1 stoi-
chiometric complex. As shown in Table 2, the 1:1 stoicho-
metric species (FL:CB[8]=0.9:1) and 2:1 homoternary species
(FL:CB[8]=3.6:1) exhibit D values of 2.86 e−10m2s−1 (D1) and
2.68 e−10m2s−1 (D2), respectively. D2 has a similar D value to
that of FGG2@CB[8], consistent with the formation of a 2:1 ho-
moternary complex (FL:CB[8]=3.6:1), where the L residues re-
side outside the CB[8] cavity. The fact that the ‘1:1’ complex ex-
hibits a larger D value than that of 2:1 ternary complex indicates
that the 1:1 stoichiometric complex is of a smaller size than that
of the 2:1 species, which verifies that the binding mode is in fact
a 1:1 pairwise inclusion complex. Moreover, D1 is very close in
value to that of both 1:1 complexes of YL@CB[8], YLA@CB[8],
and FLA@CB[8] (Table 2), providing further verification that D1
is not a case specific towards FL, but is a characteristic D for 1:1
complexes where two side-chains of the peptide are enclosed in
the same CB[8] cavity.
2.7 Peptide sequences with two effective binding pairs
To further corroborate this finding, two longer peptide sequences
were designed and synthesised to contain two CB[8] binding sites
at their termini. The first employs glycine-glycine as a spacer be-
tween YLA and ALY segments (YLAGGALY) and the second uses a
short aliphatic chain as a spacer (YLA-ahx6-ALY) (Fig. S38-S45).
If the 1:1 stoichiometric complex corresponds to a 2:2 binding
mode, the resultant complexes of YLAGGALY and YLA-ahx6-ALY
with CB[8] would contain four CB[8] molecules in the complex.
These larger complexes should exhibit a significant reduction in
their D value and differ from that of complexes containing one
or two CB[8] macrocycles. However, the association of CB[8]
with either YLAGGALY or YLA-ahx6-ALY have D values around
2.00 e−10m2s−1, which is very similar to that of the 2:2 binding
mode of VNMe2 with CB[8] and represents a complex containing
two CB[8] moieties. This observation further verifies the forma-
tion of a pairwise inclusion complex for the 1:1 stoichiometric
complexation.
3 Conclusions
Through a systematic study on the effect of sequence towards the
binding mode of oligopeptide-CB[8] complexation, we found the
dipeptide FL has the capability to initially form a 1:1 stoichiomet-
ric complex, characteristic of YLA@CB[8], which upon addition
of excess peptide, forms a 2:1 homoternary complex similar to
that of FGG2@CB[8]. This unique two-stage binding process al-
lowed us to compare size-based diffusion properties of these two
binding modes using the same dipeptide with only one change in
the system: the dipeptide-CB[8] ratio. A singular change ensures
that the small differences in diffusion coefficients observed by
DOSY NMR are only correlated to the difference between individ-
ual binding modes. From the D values obtained we verified that
the 1:1 stoichometric binding mode characteristic of YLA@CB[8]
is in fact a 1:1 binary complex with am intramolecular pair in-
clusion rather than a 2:2 quaternary complex. These findings
emphasise the importance of peptide/biomolecule design when
considering a desired binding mode in applications that utilise
host-guest binding motifs. In simple terms, using these princi-
ples we are able to customise the self-assembly pathway of pep-
tides with CB[8] through simple changes in oligopeptide design.
This will act as a useful toolbox in the design of peptide@CB[8]
supramolecular complexes for future biomedical applications.
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